Catalog No.
DHF92401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM
Concentration
1.31 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q02223
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BCMA, 2857916, GSK2857916, J6M0, J6M0-mcMMAF, CAS: 2061894-48-0
Clone ID
Belantamab
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study, PMID: 31859245
Belantamab Mafodotin: First Approval, PMID: 32936437
Belantamab Mafodotin-blmf, PMID: 32959867
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma, PMID: 33179377
Belantamab Mafodotin, PMID: 32816421
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study, PMID: 32712806
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study, PMID: 33097687
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma, PMID: 32875817
Antibodies to watch in 2020, PMID: 31847708
BCMA-targeted immunotherapy for multiple myeloma, PMID: 32943087
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma, PMID: 33403093
Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery, PMID: 33222774
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches, PMID: 32055000
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety, PMID: 34103900
Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients, PMID: 33306485
Bispecifics, trispecifics, and other novel immune treatments in myeloma, PMID: 33275733
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects, PMID: 33494319
B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma, PMID: 32707894
How I treat relapsed and/or refractory multiple myeloma, PMID: 33042504
Belantamab mafodotin detection by MASS-FIX and immunofixation, PMID: 34114387
[Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin], PMID: 33454122
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial, PMID: 32107339
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma, PMID: 34046363
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor, PMID: 34434061
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial, PMID: 30442502
Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma, PMID: 34234609
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study, PMID: 32920777
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design, PMID: 33682447
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study, PMID: 30894515
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti-Tumor Responses In Vivo, PMID: 34253590
Anti-BCMA Therapy Endorsed, despite Eye Toxicity, PMID: 32759303
Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma, PMID: 34076364
[Multiple myeloma: a focus on drugs under development], PMID: 32507818
Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography, PMID: 34169181
Antibody-drug conjugates for multiple myeloma, PMID: 32729730
Hitting a New Target in Multiple Myeloma, PMID: 33206990
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM), PMID: 34039952
[New treatments present new challenges : Ocular side effects of belantamab mafodotin], PMID: 33978807
Uveal effusion syndrome secondary to belantamab mafodotin in a patient treated for refractory myeloma, PMID: 34384623
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study, PMID: 34314018
Current antibody-based therapies for the treatment of multiple myeloma, PMID: 33406065
Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021, PMID: 33216972
Current developments in the combination therapy of relapsed/refractory multiple myeloma, PMID: 32969752
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes, PMID: 33291602
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma, PMID: 33896344
Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma, PMID: 33206992
[Multiple myeloma-soon curable?], PMID: 33783581
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses, PMID: 32153224
An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma, PMID: 33412948
Rethinking mechanisms of neurotoxicity with BCMA directed therapy, PMID: 34461271
For research use only. Not for human or drug use.
